Passive targeting of phosphatiosomes increases rolipram delivery to the lungs for treatment of acute lung injury: An animal study

Chia Lang Fang, Chih Jen Wen, Ibrahim A. Aljuffali, Calvin T. Sung, Chun Lin Huang, Jia You Fang

研究成果: 雜誌貢獻文章

9 引文 (Scopus)

摘要

A novel nanovesicle carrier, phosphatiosomes, was developed to enhance the targeting efficiency of phosphodiesterase 4 (PDE4) inhibitor to the lungs for treating acute lung injury (ALI) by intravenous administration. Phosphatiosomes were the basis of a niosomal system containing phosphatidylcholine (PC) and distearoylphosphatidylethanolamine polyethylene glycol (DSPE-PEG). Rolipram was used as the model drug loaded in the phosphatiosomes. Bioimaging, biodistribution, activated neutrophil inhibition, and ALI treatment were performed to evaluate the feasibility of phosphatiosomes as the lung-targeting carriers. An encapsulation percentage of > 90% was achieved for rolipram-loaded nanovesicles. The vesicle size and zeta potential of the phosphatiosomes were 154 nm and - 34 mV, respectively. Real-time imaging in rats showed a delayed and lower uptake of phosphatiosomes by the liver and spleen. Ex vivo bioimaging demonstrated a high accumulation of phosphatiosomes in the lungs. In vivo biodistribution exhibited increased lung accumulation and reduced brain penetration of rolipram in phosphatiosomes relative to the control solution. Phosphatiosomes improved the lungs/brain ratio of the drug by more than 7-fold. Interaction with pulmonary lipoprotein surfactants and the subsequent aggregation may be the mechanisms for facilitating lung targeting by phosphatiosomes. Rolipram could continue to inhibit active neutrophils after inclusion in the nanovesicles by suppressing O2- generation and elevating cAMP. Phosphatiosomes significantly alleviated ALI in mice as revealed by examining their pulmonary appearance, edema, myeloperoxidase (MPO) activity, and histopathology. This study highlights the potential of nanovesicles to deliver the drug for targeting the lungs and attenuating nervous system side effects.

原文英語
頁(從 - 到)69-78
頁數10
期刊Journal of Controlled Release
213
DOIs
出版狀態已發佈 - 七月 10 2015

指紋

Rolipram
Acute Lung Injury
Lung
Therapeutics
Neutrophils
Phosphodiesterase 4 Inhibitors
Pulmonary Surfactants
Brain
Pulmonary Edema
Drug Delivery Systems
Phosphatidylcholines
Pharmaceutical Preparations
Intravenous Administration
Nervous System
Peroxidase
Lipoproteins
Spleen
Liver

ASJC Scopus subject areas

  • Pharmaceutical Science

引用此文

Passive targeting of phosphatiosomes increases rolipram delivery to the lungs for treatment of acute lung injury : An animal study. / Fang, Chia Lang; Wen, Chih Jen; Aljuffali, Ibrahim A.; Sung, Calvin T.; Huang, Chun Lin; Fang, Jia You.

於: Journal of Controlled Release, 卷 213, 10.07.2015, p. 69-78.

研究成果: 雜誌貢獻文章

Fang, Chia Lang ; Wen, Chih Jen ; Aljuffali, Ibrahim A. ; Sung, Calvin T. ; Huang, Chun Lin ; Fang, Jia You. / Passive targeting of phosphatiosomes increases rolipram delivery to the lungs for treatment of acute lung injury : An animal study. 於: Journal of Controlled Release. 2015 ; 卷 213. 頁 69-78.
@article{93dce1fb7bdf4df9ad899c50ba9945c2,
title = "Passive targeting of phosphatiosomes increases rolipram delivery to the lungs for treatment of acute lung injury: An animal study",
abstract = "A novel nanovesicle carrier, phosphatiosomes, was developed to enhance the targeting efficiency of phosphodiesterase 4 (PDE4) inhibitor to the lungs for treating acute lung injury (ALI) by intravenous administration. Phosphatiosomes were the basis of a niosomal system containing phosphatidylcholine (PC) and distearoylphosphatidylethanolamine polyethylene glycol (DSPE-PEG). Rolipram was used as the model drug loaded in the phosphatiosomes. Bioimaging, biodistribution, activated neutrophil inhibition, and ALI treatment were performed to evaluate the feasibility of phosphatiosomes as the lung-targeting carriers. An encapsulation percentage of > 90{\%} was achieved for rolipram-loaded nanovesicles. The vesicle size and zeta potential of the phosphatiosomes were 154 nm and - 34 mV, respectively. Real-time imaging in rats showed a delayed and lower uptake of phosphatiosomes by the liver and spleen. Ex vivo bioimaging demonstrated a high accumulation of phosphatiosomes in the lungs. In vivo biodistribution exhibited increased lung accumulation and reduced brain penetration of rolipram in phosphatiosomes relative to the control solution. Phosphatiosomes improved the lungs/brain ratio of the drug by more than 7-fold. Interaction with pulmonary lipoprotein surfactants and the subsequent aggregation may be the mechanisms for facilitating lung targeting by phosphatiosomes. Rolipram could continue to inhibit active neutrophils after inclusion in the nanovesicles by suppressing O2- generation and elevating cAMP. Phosphatiosomes significantly alleviated ALI in mice as revealed by examining their pulmonary appearance, edema, myeloperoxidase (MPO) activity, and histopathology. This study highlights the potential of nanovesicles to deliver the drug for targeting the lungs and attenuating nervous system side effects.",
keywords = "Acute lung injury, Lung, Niosomes, Phosphatiosomes, Rolipram",
author = "Fang, {Chia Lang} and Wen, {Chih Jen} and Aljuffali, {Ibrahim A.} and Sung, {Calvin T.} and Huang, {Chun Lin} and Fang, {Jia You}",
year = "2015",
month = "7",
day = "10",
doi = "10.1016/j.jconrel.2015.06.038",
language = "English",
volume = "213",
pages = "69--78",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Passive targeting of phosphatiosomes increases rolipram delivery to the lungs for treatment of acute lung injury

T2 - An animal study

AU - Fang, Chia Lang

AU - Wen, Chih Jen

AU - Aljuffali, Ibrahim A.

AU - Sung, Calvin T.

AU - Huang, Chun Lin

AU - Fang, Jia You

PY - 2015/7/10

Y1 - 2015/7/10

N2 - A novel nanovesicle carrier, phosphatiosomes, was developed to enhance the targeting efficiency of phosphodiesterase 4 (PDE4) inhibitor to the lungs for treating acute lung injury (ALI) by intravenous administration. Phosphatiosomes were the basis of a niosomal system containing phosphatidylcholine (PC) and distearoylphosphatidylethanolamine polyethylene glycol (DSPE-PEG). Rolipram was used as the model drug loaded in the phosphatiosomes. Bioimaging, biodistribution, activated neutrophil inhibition, and ALI treatment were performed to evaluate the feasibility of phosphatiosomes as the lung-targeting carriers. An encapsulation percentage of > 90% was achieved for rolipram-loaded nanovesicles. The vesicle size and zeta potential of the phosphatiosomes were 154 nm and - 34 mV, respectively. Real-time imaging in rats showed a delayed and lower uptake of phosphatiosomes by the liver and spleen. Ex vivo bioimaging demonstrated a high accumulation of phosphatiosomes in the lungs. In vivo biodistribution exhibited increased lung accumulation and reduced brain penetration of rolipram in phosphatiosomes relative to the control solution. Phosphatiosomes improved the lungs/brain ratio of the drug by more than 7-fold. Interaction with pulmonary lipoprotein surfactants and the subsequent aggregation may be the mechanisms for facilitating lung targeting by phosphatiosomes. Rolipram could continue to inhibit active neutrophils after inclusion in the nanovesicles by suppressing O2- generation and elevating cAMP. Phosphatiosomes significantly alleviated ALI in mice as revealed by examining their pulmonary appearance, edema, myeloperoxidase (MPO) activity, and histopathology. This study highlights the potential of nanovesicles to deliver the drug for targeting the lungs and attenuating nervous system side effects.

AB - A novel nanovesicle carrier, phosphatiosomes, was developed to enhance the targeting efficiency of phosphodiesterase 4 (PDE4) inhibitor to the lungs for treating acute lung injury (ALI) by intravenous administration. Phosphatiosomes were the basis of a niosomal system containing phosphatidylcholine (PC) and distearoylphosphatidylethanolamine polyethylene glycol (DSPE-PEG). Rolipram was used as the model drug loaded in the phosphatiosomes. Bioimaging, biodistribution, activated neutrophil inhibition, and ALI treatment were performed to evaluate the feasibility of phosphatiosomes as the lung-targeting carriers. An encapsulation percentage of > 90% was achieved for rolipram-loaded nanovesicles. The vesicle size and zeta potential of the phosphatiosomes were 154 nm and - 34 mV, respectively. Real-time imaging in rats showed a delayed and lower uptake of phosphatiosomes by the liver and spleen. Ex vivo bioimaging demonstrated a high accumulation of phosphatiosomes in the lungs. In vivo biodistribution exhibited increased lung accumulation and reduced brain penetration of rolipram in phosphatiosomes relative to the control solution. Phosphatiosomes improved the lungs/brain ratio of the drug by more than 7-fold. Interaction with pulmonary lipoprotein surfactants and the subsequent aggregation may be the mechanisms for facilitating lung targeting by phosphatiosomes. Rolipram could continue to inhibit active neutrophils after inclusion in the nanovesicles by suppressing O2- generation and elevating cAMP. Phosphatiosomes significantly alleviated ALI in mice as revealed by examining their pulmonary appearance, edema, myeloperoxidase (MPO) activity, and histopathology. This study highlights the potential of nanovesicles to deliver the drug for targeting the lungs and attenuating nervous system side effects.

KW - Acute lung injury

KW - Lung

KW - Niosomes

KW - Phosphatiosomes

KW - Rolipram

UR - http://www.scopus.com/inward/record.url?scp=84936792306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936792306&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2015.06.038

DO - 10.1016/j.jconrel.2015.06.038

M3 - Article

C2 - 26164036

AN - SCOPUS:84936792306

VL - 213

SP - 69

EP - 78

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -